Could the FDA approval of Auvelity usher in a new class of antidepressants? The new oral treatment for depression works with the glutamate receptor NMDA.
In the 1950s and early 1960s, researchers within both academic and governmental institutions extensively investigated the clinical potential of psychedelic drugs, notably both LSD and psilocybin, the psychoactive substance in “magic mushrooms.” This early research aimed to understand the biological underpinnings of schizophrenia and to find new treatments for psychological disorders such as depression, anxiety...
Depression is a challenging condition to treat. Most antidepressants take four to six weeks to take effect, and patient response to such drugs varies widely from person to person. As a result, most patients must try several drugs over a period of months before they can find relief. In March, the U.S. Food and Drug...
Depression is a difficult problem for drug developers. Current marketed antidepressants are effective for a relatively small percentage of patients (about 20 in 100) and most require weeks of treatment to show an effect. Patients often need to try several drugs to find one that works for them, and some patients do not respond to...
Adherence to prescription drug therapies is a big problem, not only for patients and drug developers, but also for payers who cover the costs of such medications and then pay to treat problems the drugs were meant to prevent. About 10 years ago, the New England Journal of Medicine estimated that up to two-thirds of...